The Institute for Clinical and Economic Review (ICER) announced this week its plans to review treatments for cystic fibrosis, as well as examine any new data on FDA-approved treatments.
According to a press release, the organization will examine Vertex Pharmaceuticals’ elexacaftor, tezacaftor and ivacaftor. ICER will also consider any new data on Symdeko, Orkambi and Kalydeco.
ICER is accepting stakeholder feedback until 5 p.m. EST Sept. 25.
To read the full press release, click here.